Back to top

Cardiol ARCHER study not statistically significant, says Canaccord

Canaccord says that while the top-line results from Cardiol Therapeutics (CRDL)’ Phase II ARCHER trial in patients with acute myocarditis showed a ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Cardiol Therapeutics Inc. (CRDL)